No News Is Good News For Wyeth: Smooth Quarter Will Beat Expectations
Executive Summary
A lack of "negative surprises" for Wyeth during the first quarter is contributing to financial results well above analyst estimates, the company said
You may also be interested in...
Wyeth More Optimistic About Medicare Rx; Protonix May Benefit
Wyeth is becoming more optimistic about the potential upside of the Medicare prescription drug benefit, Wyeth North America President Joseph Mahady said during the Smith Barney Citigroup Healthcare Conference in Washington, D.C. March 30
Wyeth More Optimistic About Medicare Rx; Protonix May Benefit
Wyeth is becoming more optimistic about the potential upside of the Medicare prescription drug benefit, Wyeth North America President Joseph Mahady said during the Smith Barney Citigroup Healthcare Conference in Washington, D.C. March 30
Prevnar full dose schedule restored
The Centers for Disease Control & Prevention reinstates full four-dose schedule for Wyeth's pneumococcal conjugate vaccine Prevnar Sept. 16. CDC recommended deferring the third and fourth doses because of supply problems; it reinstated the third dose recommendation in July (1"The Pink Sheet" July 12, 2004, In Brief). Wyeth CEO Robert Essner told the Bear Stearns health care conference Sept. 14 that Prevnar's supply issues were "under good control"...